Corrigendum to ‘TAZ is indispensable for c-MYC-induced hepatocarcinogenesis’ [J Hepatol (2022) 123–134]

It has come to our attention that we inadvertently used the same western blot images for c-MYC and GAPDH in Fig. 1A of this article and in Fig. 1C of another paper by our group (Wang et al., Cell Death Dis. 2021; 12(2): 200). To avoid any confusion and future problems we have re-run the western blots for Fig. 1A of this paper. The new Fig. 1A is included below. We apologise for any inconvenience caused.

Fig. 1. Activation of the YAP/TAZ cascade in c-Myc driven HCC in mice.

(A) Western blotting results of LAST1, LATS2, and YAP/TAZ expression in the NL and c-Myc HCC tissues (T). (B) mRNA expression of Ctgf and Cyr61. (C) Western blotting results of nuclear YAP (n-YAP) and nuclear TAZ (n-TAZ) levels. Histone H3 and β-Tubulin were used as nuclear and cytoplasmic (Cyto) protein loading controls, respectively. (D) Quantification of nuclear YAP (n-YAP) and nuclear Taz (n-TAZ) levels. (E) Yap and Taz (Wwtr1) mRNA relative expression in NL and T tissues. N = 4 biological replicates for each group. (F) Representative immunohistochemistry of a c-Myc mouse tumor lesion (T) exhibiting robust nuclear immunoreactivity for c-MYC and TAZ, whereas only a few tumor cells display nuclear staining for YAP. Scale bar: 100 μm. (B, D, E) Mean ± SD; Unpaired t test, Welch’s t test or Mann-Whitney test. HCC, hepatocellular carcinoma; NL, normal liver; T, tumor.